fbpx

Type to search

CanSinoBIO’s mRNA Covid Vaccine Cleared For Trials in China

Chinese vaccine developer CanSino Biologics said on Monday its potential Covid-19 vaccine using mRNA technology has been approved by the medical products regulator to enter clinical trials


A sign of China's vaccine specialist CanSino Biologics is seen at the group's headquarters in Tianjin, August 17, 2020. File photo: Thomas Peter, Reuters.

 

Chinese vaccine developer CanSino Biologics Inc (CanSinoBIO) said on Monday its potential Covid-19 vaccine using the messenger RNA (mRNA) technology has been approved by China’s medical products regulator to enter clinical trials.

Unlike other major countries, China is yet to approve any foreign-made mRNA vaccines such as that produced by US-German duo Pfizer Inc and BioNTech SE.

With around 88% of its 1.4 billion population already vaccinated, China is trialling several domestically developed mRNA vaccine candidates, including one candidate that is being tested in a large, Phase 3 clinical trial.

CanSinoBIO said in a press release that studies before clinical trials had showed the candidate can elicit high-level neutralising antibodies against multiple variants, including Omicron.

CSPC Pharmaceutical Group Ltd said on Sunday that its potential mRNA Covid vaccine SYS6006 was cleared by China’s National Medical Products Administration to conduct clinical trials.

 

• Reuters with additional editing by Jim Pollard

 

ALSO on AF:

 

China Sends Army, Medics to Aid Shanghai’s Covid Clampdown

 

Omicron Variant Puts China’s mRNA Jab Programme in Doubt

 

China rolls out vaccine passports to kickstart international travel

 

 

Jim Pollard

Jim Pollard is an Australian journalist based in Thailand since 1999. He worked for News Ltd papers in Sydney, Perth, London and Melbourne before travelling through SE Asia in the late 90s. He was a senior editor at The Nation for 17+ years and has a family in Bangkok.

logo

AF China Bond